De-Escalation Dual Antiplatelet Strategy in Stabilized Myocardial Infarction Patients With Diabetes Mellitus

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Diabetes mellitus (DM) patients exhibit suboptimal clopidogrel response and increased thrombotic risk.
• The efficacy of early dual antiplatelet therapy (DAPT) de-escalation in DM patients with myocardial infarction (MI) post-percutaneous coronary intervention (PCI) is not well-established.

Purpose of the Study:

• To evaluate the clinical benefit of a 1-month unguided de-escalation from ticagrelor to clopidogrel compared to continued ticagrelor-based DAPT in MI patients with DM.

Main Methods:

• A post hoc analysis of the TALOS-AMI trial included 859 DM patients who completed 1 month of ticagrelor-based DAPT post-PCI.
• Patients were randomized to either continue ticagrelor or switch to clopidogrel for 11 months.
• The primary endpoint combined ischemic events (cardiovascular death, MI, stroke) and bleeding events (BARC types 2, 3, or 5).

Main Results:

• De-escalation to clopidogrel was associated with a lower primary endpoint incidence, primarily due to reduced BARC type 2 bleeding, regardless of diabetes status.
• In the DM cohort, de-escalation showed non-significant trends towards reduced bleeding (HR: 0.48) and ischemic events (HR: 0.57).
• Significant interactions between treatment and DM were noted for BARC type 3/5 bleeding (P=0.042) and target vessel revascularization (P=0.014).

Conclusions:

• One-month de-escalation to clopidogrel in MI patients with DM appears to offer clinical benefits without elevating ischemic risk.
• These findings suggest a potential benefit of this de-escalation strategy in DM patients, warranting further prospective investigation.